Tumor necrosis factor receptor 2

Source: Wikipedia, the free encyclopedia.
TNFRSF1B
Available structures
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl

ENSG00000028137

ENSMUSG00000028599

UniProt

P20333

P25119

RefSeq (mRNA)

NM_001066

NM_011610

RefSeq (protein)

NP_001057

NP_035740

Location (UCSC)Chr 1: 12.17 – 12.21 MbChr 4: 144.94 – 144.97 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Tumor necrosis factor receptor 2 (TNFR2), also known as tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) and CD120b, is one of two membrane receptors that binds

tumor necrosis factor-alpha (TNFα).[5][6] Like its counterpart, tumor necrosis factor receptor 1 (TNFR1), the extracellular region of TNFR2 consists of four cysteine-rich domains which allow for binding to TNFα.[7][8] TNFR1 and TNFR2 possess different functions when bound to TNFα due to differences in their intracellular structures, such as TNFR2 lacking a death domain (DD).[7]

Function

The protein encoded by this gene is a member of the

ubiquitination and degradation of TNF-receptor-associated factor 2 (TRAF2), which mediates anti-apoptotic signals. Knockout studies in mice also suggest a role of this protein in protecting neurons from apoptosis by stimulating antioxidative pathways.[9]

Clinical significance

CNS

At least partly because TNFR2 has no intracellular death domain, TNFR2 is neuroprotective.[10]

Patients with schizophrenia have increased levels of soluble tumor necrosis factor receptor 2 (

sTNFR2).[11]

Cancer

Targeting of TNRF2 in tumor cells is associated with increased tumor cell death and decreased progression of tumor cell growth.[8]

Increased expression of TNFR2 is found in breast cancer, cervical cancer, colon cancer, and renal cancer.[8] A link between the expression of TNRF2 in tumor cells and late-stage cancer has been discovered.[8] TNFR2 plays a significant role in tumor cell growth as it has been found that the loss of TNFR2 expression is linked with increased death of associated tumor cells and a significant standstill of further growth.[8] There is therapeutic potential in the targeting of TNFR2 for cancer treatments through TNFR2 inhibition.[12]

Systemic Lupus Erythematous (SLE)

A small scale study of 289 Japanese patients suggested a minor increased predisposition from an amino acid substitution of the 196 allele at exon 6. Genomic testing of 81

SLE patients and 207 healthy patients in a Japanese study showed 37% of SLE patients had a polymorphism on position 196 of exon 6 compared to 18.8% of healthy patients. The TNFR2 196R allele polymorphism suggests that even one 196R allele results in increased risk for SLE. [13]

Interactions

TNFRSF1B has been shown to

interact
with:

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000028137 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028599 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. S2CID 36187863
    .
  6. PMID 8702885
    .
  7. ^
    PMID 24350291
    .
  8. ^
    PMID 29892300
    .
  9. ^ "Entrez Gene: TNFRSF1B tumor necrosis factor receptor superfamily, member 1B". Retrieved 8 May 2017.
  10. PMID 18774186
    .
  11. PMID 29529289
    .
  12. S2CID 75139844
    .
  13. PMID 10395102
    .
  14. S2CID 11683986
    .
  15. PMID 7639698
    .
  16. PMID 8702708
    .
  17. PMID 11907088
    .
  18. PMID 8710854
    .
  19. PMID 9162022
    .
  20. PMID 18671942
    .
  21. PMID 10764746
    .

Further reading

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tumor_necrosis_factor_receptor_2&oldid=1192118832"